Peer-reviewedLicence not stated3 Biotech
A-to-I editing modifies the target and role of miR-376a-3p in papillary thyroid cancer
5 affiliations
- 1Department of Thyroid Surgery, The Third Affiliated Hospital of Nanjing Medical University, Changzhou Second People′s Hospital, Changzhou, 213003 Jiangsu China
- 2Department of Nuclear Medicine, Changzhou Cancer (Fourth People’s) Hospital, Changzhou, 213001 Jiangsu China
- 3Department of General Surgery, The Third Affiliated Hospital of Nanjing Medical University, Changzhou Second People′s Hospital, Changzhou, 213003 Jiangsu China
- 4Department of General Surgery, Haimen People’s Hospital, Nantong, 226199 Jiangsu China
- 5Department of thyroid and breast surgery, Shanghai Tenth People’s Hospital, Clinical Medical College of Nanjing Medical University, 301 Yanchang Middle Road, Shanghai, 200072 China
Related
- METTL7B-Mediated m6A Modification of PLEKHA4 Suppresses Ferroptosis via Reducing AURKA Ubiquitination to Promote Papillary Thyroid Cancer Progression.
- LAT1 Inhibition with JPH203 Modifies Early Cellular Responses to X-Ray Irradiation in TPC-1 Thyroid Cancer Cells
- Severity-dependent and sex-biased dysregulation of A-to-I RNA editing in COVID-19 reveals CTSS as a key regulatory target.
- Beyond Taxonomy: Fungal Nutraceutical Supplementation Modifies the Functional Potential of the Gut Microbiome in Colorectal Cancer
- Protocol for eVLP-mediated CRISPR-Cas9 and prime editing in pancreatic cancer cell lines
BibTeX
@article{yan2026atoi,
title = {{A-to-I editing modifies the target and role of miR-376a-3p in papillary thyroid cancer}},
author = {Xiaoyi Yan and Xibao Mao and Chunfu Zhu and Guojun Lv and Xiang Geng and Wenze Wu and Yu Ding and Shichen Qin and Xiaoyong Wang and Yuan Li and Lin Fang},
journal = {3 Biotech},
year = {2026},
month = sep,
doi = {10.1007/s13205-026-04984-9},
url = {https://doi.org/10.1007/s13205-026-04984-9},
}
RIS
TY - JOUR
TI - A-to-I editing modifies the target and role of miR-376a-3p in papillary thyroid cancer
AU - Xiaoyi Yan
AU - Xibao Mao
AU - Chunfu Zhu
AU - Guojun Lv
AU - Xiang Geng
AU - Wenze Wu
AU - Yu Ding
AU - Shichen Qin
AU - Xiaoyong Wang
AU - Yuan Li
AU - Lin Fang
PY - 2026
DA - 2026/09/01
JO - 3 Biotech
DO - 10.1007/s13205-026-04984-9
UR - https://doi.org/10.1007/s13205-026-04984-9
SN - 2190-572X
SN - 2190-5738
ER -